A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy

Trial Profile

A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 May 2018

At a glance

  • Drugs WVE 210201 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man
  • Sponsors WaVe life Sciences
  • Most Recent Events

    • 03 May 2018 New source identified and integrated (European Clinical Trials Database; EudraCT2017-002686-21).
    • 12 Mar 2018 According to a WaVe life Sciences media release, Safety data from the trial are anticipated in Q3 2018 and expected to facilitate the rapid transition to an open-label extension study and efficacy study.
    • 09 Nov 2017 According to a WaVe life Sciences media release, this study including an open-label extension study are designed to include an interim efficacy readout of dystrophin expression from muscle biopsies in 2H 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top